New Study in Journal of Applied Laboratory Medicine Supports Benefits of Longhorn’s PrimeStore MTM® with Roche cobas Liat® System for Detection of SARS-CoV-2 and Influenza
BETHESDA, Maryland – (COMMERCIAL THREAD) –Longhorn vaccines and diagnostics, a private biotechnology company developing molecular-based collection and test reagents, today announced the results of a major study in the Journal of Applied Laboratory Medicine of the American Association for Clinical Chemistry (Oxford Academia). The research article, “Rapid and Safe Detection of SARS-CoV-2 Virus and Influenza RNA Using Onsite qPCR Diagnostic Tests from Clinical Samples Collected in Transport Media Molecular Transport ”, is the first published study to bridge the PrimeStore molecular transport medium.® (MTM), an FDA-cleared collection device, with the cobas Liat from Roche®, an FDA-approved point-of-care diagnostic system for the simultaneous detection of SARS-CoV-2 (COVID-19) and influenza A / B viruses.
For SARS-CoV-2 and influenza A / B viruses, the need for safe sample testing, which includes RNA / DNA inactivation, is important to preserve the dignity of each sample and to ensure that ” ensure laboratory technicians handle secure transport tools. Since clinical swabs are inactivated and RNA / DNA is stored in PrimeStore MTM®, treatment and analysis of patient samples on Roche Liat® The system offers a safe alternative to commercial viral / universal transport medium, especially in emergency care clinics and physician offices for near patient care.
“In this study, we demonstrated that clinical nasal, pharyngeal and oral swabs collected via PrimeStore MTM® and tested by standard qPCR using CDC assays, were equivalent to those assessed by Roche’s Liat system, ”said Luke T. Daum, Ph.D., Scientific Director of Longhorn and lead author of the article. “Safely inactivate germs in PrimeStore MTM® vials is important for physicians and healthcare personnel who regularly handle, uncap and transfer patient samples into Liat® cartridges before testing.
Gerald W. Fischer, MD, Medical Director of Longhorn added, “Because the clinical presentation of influenza and COVID-19 can be very similar, it is important that healthcare providers have platforms to very precise on-site test like Roche Liat.® determine the cause of the disease and be able to provide prompt and appropriate treatment. Inactivating the sample at the time of collection provides an additional layer of security for the healthcare team. ”
To read the full study, go to the research at The Journal of Applied Laboratory Medicine: https://academic.oup.com/jalm/advance-article/doi/10.1093/jalm/jfab073/6307725?guestAccessKey=2e4f306d-e10c -4c15 -8b2f-b6cf81977ba6
About PrimeStore MTM
PrimeStore MTM (Molecule Transport Medium) was the first microbial nucleic acid storage and transport device authorized by the United States Food and Drug Administration (FDA). It is indicated to rapidly inactivate viruses (including influenza), bacteria (including Mycobacterium tuberculosis) and high-consequence veterinary pathogens (including ASFv, CSFv, FMDv, HPAI, NDv) in the sample and stabilize RNA and DNA to provide a safer and more efficient workflow for molecular testing and sequencing.
PrimeStore MTM alleviates the challenge of collecting a quality sample and transporting it safely and quickly to any laboratory capable of efficiently testing that sample using modern molecular platforms. Researchers around the world have used the device with success, including in remote areas of Nepal, India, China, South Africa, Peru, Pakistan, Papua New Guinea and Ukraine, as well as in densely populated cities such as Mumbai, Pretoria, Macao and Singapore.
PrimeStore MTM has several patents issued in the United States and around the world.
About Longhorn Vaccines and Diagnostics
Longhorn Vaccines & Diagnostics is an innovative molecular tools, testing and vaccine development company focused on meeting critical unmet needs in developed and developing countries. Longhorn’s flagship product, PrimeStore® The Molecular Transport Medium (MTM) is a patented, FDA-approved, state-of-the-art device for the collection and transport of room temperature molecular diagnostics that can help governments, global health organizations, and drug manufacturers to improve the diagnosis and treatment of highly infectious diseases such as influenza, SARS-CoV-2 and Mycobacterium tuberculosis (TB). Unlike standard devices for collecting and transporting tuberculosis specimens, PrimeStore® MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, enabling improved point-of-care and room temperature transport for molecular testing and laboratory characterization. Longhorn is based in Bethesda, Maryland, with a diagnostic research and development center in San Antonio, Texas.